Breaking Down Organo Corporation Financial Health: Key Insights for Investors

Curious how Organo Corporation (6368.T) stacks up for investors? With net sales of ¥163.27 billion in FY2025-an 8.6% increase-and trailing twelve-month revenue up 7.87% to September 30, 2025, alongside overseas electronics sales that more than doubled to ¥96.65 billion, the top line tells a compelling story; profitability metrics amplify that picture, with operating profit surging 38.0% to ¥31.12 billion (operating margin 19.1%), EBITDA at ¥34.53 billion, EPS of ¥599.15, and ROE at 21.7%, while balance-sheet strength is evidenced by total assets of ¥190.39 billion, liabilities of ¥71.01 billion (debt-to-equity ~0.59), cash and equivalents of ¥20.57 billion and a current ratio near 2.5; valuation and shareholder signals include a market cap of ¥602.37 billion, P/E of 21.86, P/S of 3.27, dividend per share ¥190 (yield 1.45%) and an average analyst 12-month target of ¥12,000 (≈1.78% upside)-explore the full breakdown to see how liquidity, leverage, risks (project delays, semiconductor demand, FX exposure) and growth levers like North American expansion and ultrapure water demand shape the investment thesis.

Organo Corporation (6368.T) - Revenue Analysis

• Electronics segment expansion: Taiwan electronics demand drove overseas electronics sales from ¥48.67 billion to ¥96.65 billion (FY2024 → FY2025), a >100% increase.
• Orders vs. revenue: Orders received rose 4.7% to ¥151.27 billion, signaling demand but with timing mismatches due to project delays.
• Project timing risk: Delays in large-scale electronics projects, domestically and internationally, could compress near-term revenue recognition despite strong order intake.
• Efficiency: Revenue per employee at ¥64.56 million suggests high productivity and scalable margins if top-line continues to grow.

Organo Corporation (6368.T) - Profitability Metrics

Key profitability indicators for Organo Corporation (6368.T) show meaningful improvement across margins, returns and cash‑flow proxies, driven by higher gross profit and operating leverage.

• Operating profit FY2025: ¥31.12 billion (up 38.0% YoY); operating margin 19.1% (↑4.1 pp).
• Return on equity (ROE) FY2025: 21.7% (↑3.3 pp YoY).
• Gross profit FY2025: ¥55.18 billion (above initial plan and prior forecast).
• Net profit margin H1 FY2026: 9.56% (↑13.00% YoY).
• EBITDA TTM (ending 2025-09-30): ¥34.53 billion (previous: ¥25.88 billion).
• EPS TTM (ending 2025-09-30): ¥599.15.

For additional context on the company's background and business model, see: Organo Corporation: History, Ownership, Mission, How It Works & Makes Money

Organo Corporation (6368.T) - Debt vs. Equity Structure

• Total assets (June 2025): ¥190.39 billion
• Total liabilities (June 2025): ¥71.01 billion (down 4.85% YoY)
• Stockholders' equity (June 2025): ¥119.38 billion (up from ¥101.93 billion)
• Total debt (TTM ending Sep 30, 2025): ¥28.15 billion (previous period: ¥22.56 billion)

• Leverage interpretation: A debt-to-equity of ~0.59 and financial leverage of ~1.59 point to conservative gearing - equity funds roughly 62% of assets, limiting solvency risk.
• Recent debt trend: Total debt rose from ¥22.56B to ¥28.15B (TTM Sep 30, 2025), signifying incremental borrowing that investors should monitor alongside earnings and cash flow coverage metrics.
• Liabilities and equity dynamics: Total liabilities fell 4.85% YoY while equity increased materially, supporting balance-sheet resilience and potential capacity for future capital deployment.

Organo Corporation (6368.T) - Liquidity and Solvency

• Cash and cash equivalents (June 2025): ¥20.57 billion (↑ 19.87% year-over-year)
• Current ratio: ~2.5 - adequate coverage of short-term liabilities
• Quick ratio: ~1.8 - sufficient liquid assets excluding inventory
• Operating cash flow (TTM to Sep 30, 2025): ¥28.80 billion
• Free cash flow (same period): ¥26.54 billion - shows internal funding capacity
• Interest coverage ratio: 10.5 - strong ability to service interest expenses

Organo Corporation (6368.T) - Valuation Analysis

Key valuation metrics provide a snapshot of how the market prices Organo relative to earnings, sales and capital efficiency.

• P/E of 21.86 suggests a moderate earnings multiple-neither deeply discounted nor expensive relative to many mature industrial peers.
• P/S of 3.27 indicates the market is assigning a premium to Organo's revenue base, reflecting expectations of above‑average margin or growth stability.
• Dividend yield (1.45%) combined with ¥190 DPS signals a shareholder‑friendly policy, though yield is modest compared with high‑income stocks.
• ROA 9.04% and ROC 11.94% point to efficient asset and capital deployment, supporting valuation multiples that are above value‑stock territory.

For company mission and strategic context: Mission Statement, Vision, & Core Values (2026) of Organo Corporation.

Organo Corporation (6368.T) Risk Factors

• Delays in large-scale electronics projects (domestic and international) have historically caused material volatility in order receipts and revenue recognition for Organo. In scenarios where one or two major customers delay procurement by 3-6 months, quarterly sales can drop by an estimated 8-15% versus plan.
• Organo's significant exposure to the electronics (semiconductor) industry means fluctuations in global semiconductor demand and pricing translate directly into topline and margin swings. A 10% downturn in semiconductor capex has been associated with roughly a 5-9% reduction in Organo's water‑and‑chemical related equipment orders in prior cycles.
• Currency exchange-rate movements-especially JPY vs USD, KRW and TWD-can materially affect reported international revenue and input costs. A 1% appreciation of the yen against a basket of major currencies typically reduces reported overseas revenue by ~0.5-0.8% on a consolidated basis, and can compress operating profit by several hundred million yen depending on hedging coverage.
• Changes in environmental regulations and industry standards (e.g., stricter wastewater discharge limits, new chemical handling rules) may force accelerated capital expenditure for compliance, R&D and retrofits. Compliance investment needs in a single fiscal year could range from low hundreds of millions to several billion yen if multiple product lines require upgrades.
• Competition in water-treatment and environmental solutions is intense - from domestic peers and global engineering firms. Pricing pressure and market-share erosion can compress gross margins; competitors with lower-cost manufacturing footprints can undercut bids in price-sensitive regions.
• Macro risk: economic slowdowns or geopolitical tensions in key markets (Japan, Taiwan, Korea, Southeast Asia) can reduce capex and postpone projects. A regional demand shock of 5-10% can translate into a double-digit percent decline in orders for Organo's project business in that region for the year.

• Operational concentration risk: a handful of large electronics customers can drive a disproportionate share of orders; loss or delay of one can materially affect quarterly performance.
• Supply-chain disruptions (raw materials, components) can delay project completion and inflate costs; procurement lead-time increases have historically added 3-7% to project costs during global shortages.
• Hedging and FX policy: Organo's existing hedging mitigates some currency risk, but incomplete coverage means short-term FX moves still influence reported earnings.
• Technology and product obsolescence risk: rapid changes in semiconductor manufacturing processes can require R&D reinvestment to keep solutions compatible with customer needs.

Organo Corporation (6368.T) - Growth Opportunities

• North American and international expansion: leveraging existing product platforms and channel partners to enter higher-margin markets outside Japan.
• Electronics and pharmaceutical UPW demand: rising semiconductor fabs and biotech/pharma manufacturing create steady, long-term demand for UPW systems, point-of-use purification, and validation services.
• Strategic partnerships: OEM and distribution agreements with global engineering firms and semiconductor/equipment suppliers can accelerate market access and co-development.
• R&D-driven innovation: targeted investment in membrane technologies, ion-exchange resins, and digital monitoring can create differentiated, higher-value solutions.
• Service and performance products: recurring revenue from maintenance, monitoring-as-a-service, and spare parts reduces volatility from project-based sales.
• Sustainability positioning: lower-energy purification processes, water-reuse systems, and green certifications enhance appeal to regulated and eco-conscious customers.

• Market penetration tactics: prioritize North America (US semiconductor clusters, biotech hubs), Taiwan/South Korea (chip-making ecosystems), and China/ASEAN (manufacturing growth), with pilot projects and local service hubs to reduce time-to-contract.
• Product roadmap focus: modular UPW units for fab-scale and lab-scale markets, end-to-end validation packages for pharma, and digital monitoring tied to aftermarket services.
• Partnership priorities: target global EPC firms for large projects, instrument/OEM suppliers for integrated solutions, and local service partners to accelerate field maintenance capacity.